Symbol="ACHL"
AssetType="Common Stock"
Name="Achilles Therapeutics PLC ADR"
Description="Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom."
CIK="1830749"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="245 HAMMERSMITH ROAD, LONDON, GB"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="40898800"
EBITDA="-67022000"
PERatio="None"
PEGRatio="None"
BookValue="4.523"
DividendPerShare="0"
DividendYield="0"
EPS="-1.83"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.177"
ReturnOnEquityTTM="-0.316"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.83"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="8.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.263"
EVToRevenue="-"
EVToEBITDA="1.59"
Beta="0.902"
num_52WeekHigh="3.45"
num_52WeekLow="0.75"
num_50DayMovingAverage="0.999"
num_200DayMovingAverage="1.2"
SharesOutstanding="39325800"
DividendDate="None"
ExDividendDate="None"
symbol="ACHL"
open="1.05"
high="1.06"
low="1.02"
price="1.04"
volume="54589.00"
latest_trading_day="2023-07-27"
previous_close="1.02"
change="0.02"
change_percent="1.9608%"
aroon_positive_momentum_days="54"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="54"
Volume_recent_avg="150761"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.86"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="54"
Aroon_momentum_negative="46"
image_negative_thumbnail_id_1="1087"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0120.jpeg"
image_negative_thumbnail_id_2="142"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0034.jpeg"
image_neutral_thumbnail_id_1="527"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_neutral_thumbnail_id_2="536"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0063.jpeg"
image_positive_thumbnail_id_1="973"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0135.jpeg"
image_positive_thumbnail_id_2="968"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0130.jpeg"
image_professor_thumbnail_id_1="1173"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
image_professor_thumbnail_id_2="1199"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
